Authors : Nidhi Dobariya; Kavya Patel; Arpan Dhimmar; Akshit Patel; Dr. Ketan Shah; Dr. Ashok Akabari; Lalit Chaudhary

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/yc8mt99h

Scribd : https://tinyurl.com/5rrmyem6

DOI : https://doi.org/10.38124/ijisrt/26May325

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Researchers have developed a streamlined and highly effective way to measure the combination of Losartan and Hydrochlorothiazide in synthetic mixtures using derivative UV-visible spectroscopy. By focusing on the "first derivative" of the light absorption at 296 nm and 331 nm, as well as the "second derivative" at 262 nm and 276 nm, the team was able to clear up the visual clutter where the two drugs' signals usually overlap. Using methanol as a solvent and standard quartz cells, the process proved to be remarkably accurate and followed established scientific laws for concentration. Beyond just being precise, the method is designed to be accessible—offering a fast, budget-friendly, and reliable alternative to more complex testing methods. After rigorous validation for consistency and sensitivity, it is clear that this approach is an ideal fit for routine laboratory evaluations and quality control.

Keywords : Losartan; Hydrochlorothiazide; UV Spectroscopy; First Derivative Method, Second Derivative Method.

References :

1. Mohammed A., Rudwan H., “Development and validation of an UV derivative spectrophotometric determination of Losartan Potassium in Tablet” Scholars Research Library 2015, 7(12):175-180
2. Kumar A., Gal P., “quantitative estimation of losartan potassium in  pharmaceutical dosage forms by uv   spectrophotometry” international j. Of research in pharmacy and chemistry 2011, 1(3) 295-302
3. Abeysekera, Maneesha C., Muditha B. Herath, Shehani H. Basnagoda, and Udaya K. Jayasundara. “Development, Validation, and Concentration Determination of Losartan Potassium Using 1D UV Visible Spectrophotometry.” Systematic Reviews in Pharmacy 13, no. 2 (February 28, 2022): 116–21.
4. ResearchGate. “(PDF) method development, validation and stability indicating studies of hydrochlorothiazide in bulk and pharmaceutical dosage form by uv- spectroscopy.” Accessed April 6, 2025.
5. Gokul, Pardeshi Jyotshana, Sonawane Kalyani Amol, Dashpute Sanket Narendra, and Wagh Sheetal Vilas. “UV Method Of Development For Estimation Of Losartan In Bulk & Marketed Formulation.” International Journal of Pharmaceutical Sciences, July 28, 2024.
6. Goel, Kapil Kumar, Nidhi Goel, Shailendra Patil, and Asmita Gajbhiye. “Development of New UV Spectrophotometric Method for Estimation of Losartan Potasium in Bulk and Tablet Dosage Form.” International Journal of Medical Sciences 2, no. 2 (March 1, 2010): 110–11.
7. A, Hapse S., Wagh V. S, Kadaskar P. T, Dokhe M. D, and Shirsath A. S. “Spectrophotometric Estimation and Validation of Hydrochlorothiazide in Tablet Dosage Forms by Using Different Solvents | Abstract.” Accessed April 6, 2025.
8. Jadhav, Rajesh S., and Jagdish S. Bharad. “Analytical method development and validation for estimation of hydrochlorothiazide content using uv- spectroscopic technique.” Journal of Advanced Scientific Research 13, no. 05 (June 30, 2022): 131–36.
9. “Method Development and Validation of Hydrochlorothiazide in Tablet Dosage Form by UV Spectroscopy | Request PDF.” ResearchGate, October 22, 2024.
10. “Method Development and Validation of Hydrochlorothiazide in Tablet Dosage Form by UV Spectroscopy | Request PDF.” ResearchGate. Accessed May 20, 2025.
11. Seemarani, Pawar, and Tamboli Ashpak. “Development and validation of UV spectrophotometric estimation of hydrochlorothiazide in bulk and tablet dosage form using area under curve method.,” 2017.
12. Maggio, Rubén M., Patricia M. Castellano, and Teodoro S. Kaufman. “A Multivariate Approach for the Simultaneous Determination of Losartan Potassium and Hydrochlorothiazide in a Combined Pharmaceutical Tablet Formulation.” Analytical and Bioanalytical Chemistry 391, no. 8 (August 1, 2008): 2949–55.
13. ResearchGate. “(PDF) Stability Indicating Spectrophotometric Methods for Simultaneous Determination of Losartan Potassium and Hydrochlorothiazide in Pharmaceuticals.” Accessed April 6, 2025.
14. ResearchGate. “Stability Indicating Spectrophotometric Methods for Simultaneous Determination of Losartan Potassium and Hydrochlorothiazide in Pharmaceuticals.” Accessed May 20, 2025.
15. Saini, Babu Lal, Pramod Kumar, Ravi Dahiya, Javed Akhtar, and Birendra Shrivastav. “Development and Validation of a UV- Spectrophotometric Method for Simultaneous Estimation of Hydrochlorothiazide and Losartan Potassium in Bulk Drug and Its Formulations.” Research Journal of Pharmacy and Technology 6, no. 3 (March 28, 2013): 260–63.
16. Al-Bazi, Abdulhakeem Abdullah Mohammed, and A Hakan Aktaş. “Determination of losartan and hydrochlorothiazide in a Combined pharmaceutical UV derivative spectrophotometric methods,” Int. j. of Natural applied sci. Volume 4, Issue December 2017
17. Dinc E. “Spectrophotometric Determination of Losartan Potassium and Hydrochlorothiazide in Tablets by Wavelet Transform Approach.” ResearchGate, December 12, 2024.
18. Lande N. R. “Simultaneous estimation of losartan potassium and hydrochlorothiazide in combined dosage form by UV spectrophotometry.” International Journal of Biology, Pharmacy and Allied Sciences 12, no. 6(June 15, 2023).
19. Womanly Magazine. “What Is Hypertension?” Accessed April 6, 2025.
20. Oparil, Suzanne, Maria Czarina Acelajado, George L. Bakris, Dan R. Berlowitz, Renata Cífková, Anna F. Dominiczak, Guido Grassi, et al. “Hypertension.” Nature Reviews. Disease Primers 4 (March 22, 2018): 18014.
21. Luft, F. C. “Twins in Cardiovascular Genetic Research.” Hypertension (Dallas, Tex.: 1979) 37, no. 2 Pt 2 (February 2001): 350–56.
22. Surendran, Praveen, Fotios Drenos, Robin Young, Helen Warren, James P. Cook, Alisa K. Manning, Niels Grarup, et al. “Trans-Ancestry Meta-Analyses Identify Rare and Common Variants Associated with Blood Pressure and Hypertension.” Nature Genetics 48, no. 10 (October 2016): 1151–61.
23. Womanly Magazine. “What Is Hypertension?” Accessed April 6, 2025.
24. “Losartan (Oral Route) - Mayo Clinic.” Accessed April 6, 2025.
25. ResearchGate. “Site of Action of Losartan in Blocking the Action of Ang II at AT1Rs....” Accessed April 6, 2025.
26. “Hydrochlorothiazide (Oral Route) - Mayo Clinic.” Accessed April 6, 2025.
27. “Thiazides_figure [TUSOM | Pharmwiki].” Accessed April 6, 2025.
28. “Losartan.” Accessed April 6, 2025.
29. Sica, Domenic A., Todd W. B. Gehr, and Siddhartha Ghosh. “Clinical Pharmacokinetics of Losartan.” Clinical Pharmacokinetics 44, no. 8 (2005): 797–814.
30. Zhou, Shu-Feng, Zhi-Wei Zhou, Li-Ping Yang, and Jian-Ping Cai. “Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development.” Current Medicinal Chemistry 16, no. 27 (2009): 3480–3675.
31. Pickkers, P., A. D. Hughes, F. G. Russel, T. Thien, and P. Smits. “Thiazide-Induced Vasodilation in Humans Is Mediated by Potassium Channel Activation.” Hypertension (Dallas, Tex.: 1979) 32, no. 6 (December 1998): 1071–76.
32. Akbari, Pegah, and Arshia Khorasani-Zadeh. “Thiazide Diuretics.” In StatPearls. Treasure Island (FL): StatPearls Publishing, 2025.
33. Analysis & Separations from Technology Networks. “UV-Vis Spectroscopy: Principle, Strengths and Limitations and Applications.” Accessed April 6, 2025.
34. ResearchGate. “(PDF) a short review on ultraviolet and visible spectroscopy.” Accessed April 6, 2025
35. Rawat, Swati, and Akhilesh Gupta. “Regulatory Requirements for Drug Development and Approval in United States: A Review.” Asian Journal of Pharmaceutical Research 1, no. 1 (March 28, 2011): 01–06.